Skip to main content

COLLEGIUM PHARMACEUTICAL INC

For the period ended Mar 31, 2024. Filed May 9, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 9, 2024

COLL$24.71+2.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 5. Other Information

Rule 10b5-1 Trading Plans

The disclosure set forth in Part II – Item 2 above is incorporated herein by reference.

The following table shows the “Rule 10b5-1 trading arrangements” or “non-Rule 10b5-1 trading arrangements” (as each term is defined in Item 408(a) of Regulation S-K) adopted, amended, or terminated by our directors and officers during the three months ended March 31, 2024:

​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Trading Arrangement · ​ · ​ · ​ · ​
Name​Title​Action​Effective Date​Rule 10b5-1​Non-Rule 10b5-1​Scheduled Expiration Date of Trading Plan (1)​Maximum Shares Subject to Trading Plan
Joseph Ciaffoni​Director, President and Chief Executive Officer​Adoption​February 26, 2024​X​​​December 31, 2024​157,285
Colleen Tupper​Executive Vice President and Chief Finance Officer​Adoption​February 26, 2024​X​​​October 31, 2024​19,710
Shirley Kuhlmann​Executive Vice President, Chief Administrative Officer, General Counsel & Secretary​Adoption​February 26, 2024​X​​​June 7, 2024​37,500
(1)A trading arrangement may expire on an earlier date if all contemplated transactions are completed before such trading arrangement’s expiration date, upon termination by broker or the holder of the trading arrangement, or as otherwise provided in the trading arrangement.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.